Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
Items 101–200 of 685
Thong, K. Y., YADAGIRI, M., Barnes, D., Morris, D. S., Chowdhury, T. A., Chuah, L. L., Robinson, A. M., Bain, S. C., Adamson, K., & Ryder, R. E. J. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.06.004 · Cited by 75
“Adverse events associated with SGLT2 inhibitor treatment include genital fungal infections, urinary tract infection, volume-related events (hypotension, syncope or dehydration), hypoglycaemia and rarely, ketoacidosis [5-7].”
BackgroundThe Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
Capozzi, M. E., Coch, R. W., Koech, J., Astapova, I. I., Wait, J. B., Encisco, S. E., Douros, J. D., EL, K. M., Finan, B., Sloop, K. W., et al. (2020) · Diabetes · doi:10.2337/db19-1216 · Cited by 65
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Mirabelli, M., CHIEFARI, E. D., Puccio, L., FOTI, D. P., & Brunetti, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103664 · Cited by 69
“When related to SGLT2 inhibition, DKA may be even more deceitful with an “euglycemic” presentation (<250 mg/dL) because of an increased urinary loss of glucose that mitigates hyperglycemia [45].”
BackgroundInformation and consensus document for the detection and management of chronic kidney disease
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Escalada, J., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.07.003 · Cited by 82
Kołodziej, D., Sobczak, Ł., & Łączkowski, K. Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137033 · Cited by 64
“…joint pain [29], empagliflozin and dapagliflozin are typically associated with an increased risk of urinary tract infections [30] and are proven to increase the risk of potentially life-threatening diabetic ketoacidosis [30,31], while pioglitazone may increase the risk of bladder cancer [32].”
BackgroundMusso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61
“Excessive insulin dose reduction plays a key role in DKA by enhancing lipolysis and ketogenesis [75], but the exact cut-off of insulin down-titration which augments DKA risk is unclear: We could not confirm the cut-offs suggested by experts (20% of initial TID or 10% of initial basal ID) [18], which were derived from…”
BackgroundMethodTratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 69
Lau, A., BRUCE, S. R., Wang, E., Ree, R. M., Rondi, K., & Chau, A. M. T. (2017) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-017-1018-6 · Cited by 59
SGLT1 inhibition: Pros and cons
Tsimihodimos, V., Filippas-Ntekouan, S., & Elisaf, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.019 · Cited by 55
Management of diabetic ketoacidosis
Barski, L., Golbets, E., Jotkowitz, A., & Schwarzfuchs, D. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.005 · Cited by 63
Evaluation and Management of the Critically Ill Adult With Diabetic Ketoacidosis
Long, B., Willis, G. C., Lentz, S. A., Koyfman, A., & Gottlieb, M. A. (2020) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2020.06.059 · Cited by 57
Evans, M., Morgan, A. R., Davies, S., Beba, H., & Strain, W. D. (2022) · Age and Ageing · doi:10.1093/ageing/afac201 · Cited by 54
“As older adults with T2DM are at increased risk of insulinopenia (osmotic symptoms, weight loss), compared to younger adults, due to the relatively longer duration of diabetes this puts them at higher risk of euglycemic ketoacidosis [43].”
BackgroundDizon, S., Keely, E. J., Malcolm, J., & Arnaout, A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.004 · Cited by 54
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 55
“Moreover, patients presenting with DKA often had a predisposing factor such as a significant concurrent illness, myocardial infarction, severe infection, stroke, surgery, or reduced insulin doses; or were experiencing stressful situations such as reduced food and fluid intake, excessive exercise, or recent alcohol int…”
BackgroundOh, R., Gilani, B., & Uppaluri, K. R. (2019) · StatPearls · Cited by 62
Yang, Y., Zhao, C., Ye, Y., Yu, M., & Qu, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00190 · Cited by 54
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“ketoacidosis without hyperglycemia.[120] At the start of therapy, there may be some symptoms related to the diuretic effect, but these adverse effects are offset by the reductions in body weight and blood pressure.”
BackgroundSGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48
Bamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48
“This is largely due to the presentation with normal or minimally elevated glucose levels making ketoacidosis more difficult to diagnose [25].”
BackgroundTreatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 54
SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
Adamczak, D., Ahmed, N., Tariq, H., Walgamage, M., WALGAMAGE, T., Mohammed, A., Chou, J. T.-T., Kałużna‐Oleksy, M., Lesiak, M., & Straburzyńska‐Migaj, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061470 · Cited by 55
“Glucagon levels subsequently increase, leading to SGLT2i-related hyperglucagonemia and ketone production [65].”
BackgroundOptimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans, M., Hicks, D., Patel, D., Patel, V., McEwan, P. C., & Dashora, U. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00728-6 · Cited by 48
Euglycemic Diabetic Ketoacidosis
Plewa, M. C., Bryant, M. G., & King-Thiele, R. (2021) · StatPearls · Cited by 73
on behalf of the Scottish Diabetes Research Network Epidemiology Group, McGurnaghan, S. J., Brierley, L., Caparrotta, T. M., McKeigue, P. M., Blackbourn, L. A. K., Wild, S. H., Leese, G. P., McCrimmon, R. J., McKnight, J. A., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4806-9 · Cited by 46
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 48
Tosaki, T., Kamiya, H., Himeno, T., Kato, Y., Kondo, M., Toyota, K., Nishida, T., Shiroma, M., Tsubonaka, K., Asai, H., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7196 · Cited by 49
“However, the risk of SGLT2 inhibitor-induced ketoacidosis was indicated in an FDA Safety Announcement (5-15-2015 (24)), and a case has been reported in Japan (4); however this was confined to cases in which the assessment of the patient’s disease status by the physician was considered to be insufficient, such as cases…”
BackgroundPfützner, A., Klonoff, D. C., Heinemann, L., Ejskjær, N., & Pickup, J. C. (2017) · Endocrine · doi:10.1007/s12020-017-1264-y · Cited by 46
Lemke, A. I., Brokmeier, H. M., Leung, S. B., Mara, K. C., Mour, G. K., Wadei, H. M., Hill, J. M., Stegall, M. D., Kudva, Y. C., Shah, P., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14718 · Cited by 44
Dey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 47
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 48
“Potential drawbacks are the less potent glucose lowering impact as kidney failure progresses [272] and an increased risk for an unspecific type of ketoacidosis, the so-called euglycemic diabetic ketoacidosis, a type of ketoacidosis with uncharacteristically mild to moderate elevations of glycemia [283].”
BackgroundCarbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 45
Alicic, R. Z., & Nicholas, S. B. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.05.003 · Cited by 48
“Factors that can trigger diabetic ketoacidosis include intercurrent illness, reduced food and fluid intake, reduced insulin doses, and alcohol consumption.(81) Clinicians and patients should also be aware that diabetic ketoacidosis may be manifested with normal or mildly elevated plasma glucose concentration (<200 mg/…”
BackgroundLeiter, L. A., Cefalu, W. T., de Bruin, T. W., Xu, J. L., Parikh, S. J., JOHNSSON, E. K., & Gause‐Nilsson, I. A. M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12666 · Cited by 46
SGLT2 inhibitor use in the management of feline diabetes mellitus
Cook, A. K., & Behrend, E. N. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13466 · Cited by 50
“It is prudent to institute insulin therapy in cats with clinical signs of clinically pancreatitis, as vomiting, decreased food intake, and a suboptimal body weight are well-established risk factors for DKA in people taking SGLT2 inhibitors (Long et al., 2021 ; Rosenstock & Ferrannini, 2015).”
InfluentialTrujillo, J. M., & Nuffer, W. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1903 · Cited by 42
“For empagliflozin, eight DKA events were reported among > 13,000 patients with T2D, with no imbalance between events reported for empagliflozin and placebo.(53) In a conference convened by the AACE/ACE to discuss the issue of SGLT2 inhibitor–associated DKA, experts concluded that “the prevalence of DKA is infrequent a…”
BackgroundInfluentialHenry, R. R., Dandona, P., Pettus, J., Mudaliar, S., Xu, J., & Hansen, L. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12882 · Cited by 42
“In addition, regardless of blood glucose and insulin, guidance from regulatory authorities suggests that monitoring of ketones should be considered in patients receiving an SGLT2 inhibitor who feel unwell or who display symptoms of DKA, and in clinical situations known to predispose patients to ketoacidosis (eg, reduc…”
BackgroundTratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 47
Yasuda, M., Iizuka, K., Kato, T., Liu, Y., Takao, K., Nonomura, K., Mizuno, M., & Yabe, D. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13137 · Cited by 43
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
McGill, J. B., & Subramanian, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.006 · Cited by 44
Peters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0924 · Cited by 44
“By decreasing renal glucose reabsorption,SGLT inhibitors inducerapid increases in urinary glucose excretion that predisposepatients to increasedketogenesis (9).”
BackgroundInfluentialFralick, M., Redelmeier, D. A., Patorno, E., Franklin, J. M., Razak, F. A., Gomes, T., & Schneeweiß, S. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06561-z · Cited by 45
“First, DKA is typically associated with type 1 diabetes mellitus, rather than type 2 diabetes.(12,32) Since SGLT2 inhibitors are prescribed to patients with Fralick et al.”
BackgroundEuglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature
Lucero, P., & Chapela, S. (2018) · Case Reports in Critical Care · doi:10.1155/2018/1747850 · Cited by 40
“In a review of literature, 46 cases of diabetic ketoacidosis associated with the use of SGLT-2 were found and, in 70%of the cases, the ketoacidosiswas euglycemic [23].”
BackgroundRamaesh, A. (2016) · Journal of the Intensive Care Society · doi:10.1177/1751143716644458 · Cited by 39
“The treatment plan for ICU admissions of DKA should be implemented within 6 h of admission: confirm diagnosis, correct hypovolaemia, resolve hyperglycaemia and correct electrolyte imbalances.10 Crucially, the underlying cause of the ketoacidosis must be identified, and the appropriate steps taken to treat it, as DKA-r…”
BackgroundInfluentialScheen, A. J. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0498-9 · Cited by 39
“DPP-4Is and SGLT2Is exert their glucose-lowering effects via different and complementary mechanisms [30, 31].”
InfluentialSGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 44
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
da Silva, J. C., Filho, J. D. S. R., Cavalcanti, C. A. J., Martins, A., & Salles, J. E. N. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00757-y · Cited by 39
(2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.04.001 · Cited by 42
Risk of diabetic ketoacidosis during Ramadan fasting: A critical reappraisal
Beshyah, S., Chowdhury, T. A., Ghouri, N., & Lakhdar, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.027 · Cited by 38
Liew, A., Lydia, A., Matawaran, B. J., Susantitaphong, P., Tran, H. T. B., & Lim, L. (2023) · Nephrology · doi:10.1111/nep.14167 · Cited by 42
“potential triggering factors for euglycaemic DKA in patients with type 2 diabetes taking SGLT-2 inhibitors, such as intercurrent illness, reduced food and fluid intake, excessive reduction in insulin doses and history of alcohol consumption.(53) In addition, the condition could also occur in the postoperative period.”
BackgroundHoenig, M. E., Clark, M., Schaeffer, D. J., & Reiche, D. (2017) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12467 · Cited by 37
“In people, euglycemic and hyperglycemic diabetic ketoacidosis (Peters et al., 2015; Rosenstock & Ferrannini, 2015) have been described in patients treated with SGLT2 inhibitors, and the FDA has included this fact in a safety announcement in 2014 after 20 cases had been described in a 1- year period…”
BackgroundSodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad
Ekanayake, P. S., Hupfeld, C. J., & Mudaliar, S. R. D. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01359-z · Cited by 38
Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
Palmer, B. F., Clegg, D. J., Taylor, S. I., & Weir, M. R. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.008 · Cited by 37
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
Candelario, N., & Wykretowicz, J. (2016) · Oxford Medical Case Reports · doi:10.1093/omcr/omw061 · Cited by 36
Cahn, A., Raz, I., Bonaca, M. P., Mosenzon, O., Murphy, S. A., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Bhatt, D. L., McGuire, D. K., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14041 · Cited by 39
“The DECLARE-TIMI 58 study is the largest and longest CV outcome study conducted with an SGLT2 inhibitor and included a F IGURE 2 (Continued) heterogeneous population of patients with T2DM.”
BackgroundInfluentialAraki, E., Onishi, Y., Asano, M., Kim, H., & Yajima, T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12853 · Cited by 38
Tamez, H. E., Tamez, A. L., Garza, L. A., Hernandez, M. I., & Polanco, A. C. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0210-x · Cited by 34
Carlson, C. J., & Santamarina, M. L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1216100 · Cited by 39
“They suggested that euglycemic ketoacidosis is similar to ‘non-euglycemic’ ketoacidosis in terms of pathophysiology, with the exception that plasma glucose concentrations are reduced in euglycemic ketoacidosis because of SGLT2 inhibitor-induced urinary glucose excretion, which then predisposes to increased ketogenesis…”
BackgroundInfluentialAdjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
“If risk factors including acute illness, increased activity, decreased carbohydrate intake and reduced insulin doses are identified, medication may be withheld.(68,70)”
BackgroundJuneja, D., Nasa, P., Jain, R., & Singh, O. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i8.1314 · Cited by 36
Dandona, P., & Chaudhuri, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12937 · Cited by 35
Eckstein, M. L., Williams, D. M., O'Neil, L., Hayes, J., Stephens, J. W., & Bracken, R. M. (2018) · Diabetic Medicine · doi:10.1111/dme.13865 · Cited by 45
“Dehydration is a concern but perhaps more serious, and 427 potentially exacerbated by dehydration is the condition of euglycaemic diabetic ketoacidosis, 428 arising because of ketone formation due to a decreased insulin-to-glucagon ratio in participants 429 using SGLT-2 inhibitors (63).”
BackgroundNon-diabetic ketoacidosis: a case series and literature review
Bashir, B., Fahmy, A. A., Raza, F., & Banerjee, M. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138513 · Cited by 37
When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Avogaro, A., Delgado, E., & Lingvay, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2981 · Cited by 35
“Furthermore, these events were often precipitated by poor nutritional intake, postoperative stress, intercurrent illness, reduction in insulin doses, or alcohol intake.(68,72) It has been suggested therefore that DKA with SGLT2 inhibitors is predictable and preventable adverse effect with careful monitoring, patient e…”
BackgroundInfluentialChacko, B., Whitley, M., Beckmann, U., Murray, K., & Rowley, M. (2018) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1804600212 · Cited by 32
Sone, H., Kaneko, T., Shiki, K., Tachibana, Y., Pfarr, E., Lee, J., & Tajima, N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13909 · Cited by 35
“Finally, there may be an increased risk of developing diabetic or euglycaemic ketoacidosis with SGLT2 inhibitor treatment,(29,30) as SGLT2 inhibitors increase glucagon levels and ketone body formation, while clearing glucose via renal excretion.(30) Furthermore, as insulin suppresses lipol-”
BackgroundBonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 36
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 33
SGLT2 Inhibitors and Safety in Older Patients
Pollack, R. M., & Cahn, A. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.002 · Cited by 33
He, Z., Lam, K., Zhao, W., Yang, S., Li, Y., Mo, J., Gao, S., Liang, D., Qiu, K., Huang, M., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-02015-6 · Cited by 35
Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
Pradhan, A. K., Vohra, S., Vishwakarma, P., & Sethi, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_232_19 · Cited by 38
“Adverse events**[25,26] Urogenital tract infections Infrequent, mild, managed with standard treatments and did not recur in any of the patients Mild to moderate in severity, tended to occur during the first 6 months of dapagliflozin therapy Urogenital infections were more common in women, generally mild to moderate in…”
BackgroundChiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
Ferner, R. E., & McGettigan, P. (2018) · BMJ · doi:10.1136/bmj.k4051 · Cited by 35
Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus
Le, J., Chen, Y., Yang, W., Chen, L., & Ye, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.004 · Cited by 30
“Other reported side effects include polyuria, urinary and reproductive tract infections, lower limb amputation, acute kidney injury, diabetic ketoacidosis, hyperkalemia, and more 188 e 191 .”
BackgroundSevere Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
Gelaye, A., Haidar, A., Kassab, C., Kazmi, S., & Sinha, P. (2016) · Case Reports in Critical Care · doi:10.1155/2016/1656182 · Cited by 29
“Rosenstock and Ferrannini [13] advise that, in any event, type 1 diabetic patients who choose to take this medication off-label should sign an informed consent that makes them fully aware of the potential for euglycemic DKA, the precipitating factors, the warning symptoms and signs, and the preventative measures to ad…”
BackgroundUtsunomiya, K., Shimmoto, N., Senda, M., Kurihara, Y., Gunji, R., Fujii, S., Kakiuchi, S., Fujiwara, H., Kameda, H., Tamura, M., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12626 · Cited by 30
Thewjitcharoen, Y., Yenseung, N., Malidaeng, A., Nakasatien, S., Chotwanvirat, P., Krittiyawong, S., Wanothayaroj, E., & Himathongkam, T. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0297-y · Cited by 33
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report
Chou, Y.-M., Seak, C., Goh, Z. N. L., Seak, J. C.-Y., Seak, C.-K., & Lin, C. (2018) · Medicine · doi:10.1097/md.0000000000011056 · Cited by 32
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
Neuen, B. L., Cherney, D. Z. I., Jardine, M., & Perkovic, V. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190047 · Cited by 32
Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus
Graczyk, P., Dach, A., Dyrka, K., & Pawlik, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095027 · Cited by 32
“These metabolic changes predispose patients to ketoacidosis while preserving normoglycaemia [73].”
BackgroundTriplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 33
SGLT-2 inhibitors: Their pleiotropic properties
Vallianou, N. G., Geladari, E. V., & Kazazis, C. E. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.003 · Cited by 32
Cintra, R. M. R., Moura, F. A., de Carvalho, L. S. F., Barreto, J., Tambascia, M. A., Pecoits‐Filho, R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.70 · Cited by 32
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management
Mancini, G. B. J., CHENG, A. Y. Y., Connelly, K. A., FITCHETT, D. H., Goldenberg, R., Goodman, S. G., Leiter, L. A., Lonn, E., Paty, B. W., Poirier, P., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.512 · Cited by 29
Type 1 diabetes: where are we in 2017?
Copenhaver, M. M., & Hoffman, R. P. (2017) · Translational Pediatrics · doi:10.21037/tp.2017.09.09 · Cited by 34
Papadopoulos, V. P., Koutroulos, M.-V., Zikoudi, D.-G., Bakola, S.-A., Avramidou, P., Touzlatzi, N., & Filippou, D. K. (2021) · Diabetology International · doi:10.1007/s13340-021-00502-9 · Cited by 31
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
“may have contributed to the cardiovascular benefits [70] could have helped to predict that severe DKA may occur in particular circumstances [78].”
BackgroundQuarella, M., Walser, D., Brändle, M., Fournier, J., & Bilz, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00082 · Cited by 30
Rosenstock, J., Perl, S., JOHNSSON, E. K., García‐Sánchez, R., & Jacob, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13795 · Cited by 30
“The greater improvements in glycaemic control seen with triple therapy than with either dual therapy regimen are consistent with other clinical studies of combination therapies, as well as with a previous study of the combination of dapagliflozin plus saxagliptin plus metformin that used dapagliflozin at the higher do…”
BackgroundResultInfluentialSelf-citationAcid-base and electrolyte disorders associated with the use of antidiabetic drugs
Filippatos, T. D., Tzavella, E., Rizos, C. V., Elisaf, M., & Liamis, G. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361400 · Cited by 33
“leading to increased renal reabsorption of ketones [84,95].”
BackgroundHatada, M., Wilson, E. D., Khanwalker, M., Probst, D., Okuda‐Shimazaki, J., & Sode, K. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.130914 · Cited by 27
Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
Solini, A. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0856-y · Cited by 28
Sodium glucose cotransporters inhibitors in type 1 diabetes
Dellepiane, S., Nasr, M. B., Assi, E., Usuelli, V., Letizia, T., D’Addio, F., Zuccotti, G., & Fiorina, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.018 · Cited by 26
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 29
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
Libianto, R., Davis, T. M. E., & Ekinci, E. I. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50472 · Cited by 27
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
“infections and less frequently urinary tract infection and the rare but potentially serious adverse effect of diabetic ketoacidosis without hyperglycemia [126], but overall they are very”
BackgroundCao, Y., Widyahening, I. S., Sun, X., & Li, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70060 · Cited by 25
“87,88 A meta-analysis suggested the changes in body weight and lean mass from using SGLT-2 inhibitors; the loss of lean mass accounted for between 10% and 40% of the body weight lost, with an average of around 30%.”
Andrews, T. J., Cox, R. D., Parker, C., & Kolb, J. C. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.07.082 · Cited by 25
Management of Endocrine Emergencies in the ICU
Jacobi, J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019834771 · Cited by 26
Limenta, L. M. G., Ho, C. S.-C., Poh, J. W. W., Goh, S., & Toh, D. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00794-5 · Cited by 28
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
John, M., Gopinath, D., & Jagesh, R. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.172268 · Cited by 25
“This releases free fatty acids and leads to subsequent ketogenesis in the liver.[54] In subjects with type 1 diabetes, reduction of insulin while adding SGLT2 inhibitors would lead to lipolysis and subsequent ketogenesis in the liver.”
Background
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.